AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients with Recurrent or Refractory Active Chronic Graft Versus Host Disease who have Received at least 2 Lines of Systemic Therapy Publicado
Se trata de un estudio de fase 2 para evaluar la eficacia, la seguridad y la tolerabilidad de axatilimab en 3 niveles de dosis diferentes en participantes con enfermedad crónica de injerto c...

